In vitro development and optimization of cell-laden injectable bioprinted gelatin methacryloyl (GelMA) microgels mineralized on the nanoscale
- PMID: 38457904
- PMCID: PMC10997158
- DOI: 10.1016/j.bioadv.2024.213805
In vitro development and optimization of cell-laden injectable bioprinted gelatin methacryloyl (GelMA) microgels mineralized on the nanoscale
Abstract
Bone defects may occur in different sizes and shapes due to trauma, infections, and cancer resection. Autografts are still considered the primary treatment choice for bone regeneration. However, they are hard to source and often create donor-site morbidity. Injectable microgels have attracted much attention in tissue engineering and regenerative medicine due to their ability to replace inert implants with a minimally invasive delivery. Here, we developed novel cell-laden bioprinted gelatin methacrylate (GelMA) injectable microgels, with controllable shapes and sizes that can be controllably mineralized on the nanoscale, while stimulating the response of cells embedded within the matrix. The injectable microgels were mineralized using a calcium and phosphate-rich medium that resulted in nanoscale crystalline hydroxyapatite deposition and increased stiffness within the crosslinked matrix of bioprinted GelMA microparticles. Next, we studied the effect of mineralization in osteocytes, a key bone homeostasis regulator. Viability stains showed that osteocytes were maintained at 98 % viability after mineralization with elevated expression of sclerostin in mineralized compared to non-mineralized microgels, showing that mineralization can effectively enhances osteocyte maturation. Based on our findings, bioprinted mineralized GelMA microgels appear to be an efficient material to approximate the bone microarchitecture and composition with desirable control of sample injectability and polymerization. These bone-like bioprinted mineralized biomaterials are exciting platforms for potential minimally invasive translational methods in bone regenerative therapies.
Keywords: Bioprinting; Bone tissue engineering; GelMA; Microgels; Mineralization; Osteocytes; Sclerostin.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Update of
-
In vitro development and optimization of cell-laden injectable bioprinted gelatin methacryloyl (GelMA) microgels mineralized on the nanoscale.bioRxiv [Preprint]. 2023 Oct 12:2023.10.10.560919. doi: 10.1101/2023.10.10.560919. bioRxiv. 2023. Update in: Biomater Adv. 2024 May;159:213805. doi: 10.1016/j.bioadv.2024.213805. PMID: 37873385 Free PMC article. Updated. Preprint.
References
-
- Baldwin P, Li DJ, Auston DA, Mir HS, Yoon RS, Koval KJ, Autograft, Allograft, and Bone Graft Substitutes: Clinical Evidence and Indications for Use in the Setting of Orthopaedic Trauma Surgery, J Orthop Trauma 33(4) (2019) 203–213. - PubMed
-
- Roddy E, DeBaun MR, Daoud-Gray A, Yang YP, Gardner MJ, Treatment of criticalsized bone defects: clinical and tissue engineering perspectives, Eur J Orthop Surg Traumatol 28(3) (2018) 351–362. - PubMed
-
- Gerry L MDAGM. Koons, Materials design for bone-tissue engineering, Nature Reviews Materials 5 (2020) 584–603.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
